Product Description
Trientine is an oral copper chelating agent used to treat Wilson disease. Trientine has not been associated with worsening of serum enzyme elevations during therapy or with cases of clinically apparent liver injury with jaundice. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31643449/)
Mechanisms of Action: Copper Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Canada | Croatia | Czech | Denmark | Estonia | Finland | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Sweden | Switzerland
Approved Indications: None
Known Adverse Events: None
Company: Orphalan
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Heart Failure, Chronic|Heart Failure, Systolic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20211406 |
CTR20211406 | P2 |
Active, not recruiting |
Heart Failure, Chronic|Heart Failure, Systolic |
None |
2025-04-29 |
Patient Enrollment|Start Date |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/07/2025 |
News Article |
Orphalan becomes the first European company to enter in China's Wilson Disease market |
|
12/23/2024 |
News Article |
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease |
|
10/24/2024 |
News Article |
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate |
|
08/19/2024 |
News Article |
Behind The Mystery Unveils Treatment in Wilson Disease with Cuviror® by Orphalan |